Pfizer (PFE)
24.38
+0.41 (1.69%)
NYSE · Last Trade: Jun 10th, 1:18 PM EDT
Detailed Quote
Previous Close | 23.97 |
---|---|
Open | 23.97 |
Bid | 24.37 |
Ask | 24.38 |
Day's Range | 23.96 - 24.38 |
52 Week Range | 20.92 - 31.54 |
Volume | 19,693,473 |
Market Cap | 136.66B |
PE Ratio (TTM) | 17.66 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.720 (7.06%) |
1 Month Average Volume | 41,391,287 |
Chart
About Pfizer (PFE)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
News & Press Releases
Shares look likely to break out at the open after the biotech company unveiled promising results for a pulmonary arterial hypertension treatment.
Via Investor's Business Daily · June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
Via Stocktwits · June 10, 2025
A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.
Via Investor's Business Daily · June 9, 2025
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
Explore the S&P500 index on Monday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · June 9, 2025
The meeting follows an executive order from President Trump last month, which directed drugmakers to lower medicine prices to the levels paid by other high-income countries.
Via Stocktwits · June 9, 2025
Via Benzinga · June 9, 2025
Via The Motley Fool · June 8, 2025

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients
Via Benzinga · June 6, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health experts call a dichotomy in his approach to healthcare policy.
Via Benzinga · June 6, 2025

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –
By Arvinas Inc. · Via GlobeNewswire · June 6, 2025

Via The Motley Fool · June 5, 2025

A volatile stock market represents an ideal opportunity for long-term investors to pounce.
Via The Motley Fool · June 5, 2025
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
American pharmaceutical and biotech company Pfizer has been sued by hundreds of American and UK women after a recent study revealed that a contraceptive injection developed by the company increased their risk of developing brain tumors significantly. Four hundred American women have already filed the lawsuit in a Florida county, and around 200 women from the UK are also considering suing the pharmaceutical firm, the Daily Mail reports.
Via Investor Brand Network · June 4, 2025

Nearly 80% of S&P 500 firms beat Q1 earnings forecasts. Profit growth hit 13.3%, led by tech and health care, says FactSet.
Via Benzinga · June 3, 2025

Apple and Cisco could generate surprising gains over the next few years.
Via The Motley Fool · June 3, 2025

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.
Via The Motley Fool · June 3, 2025

Bristol Myers Squibb just agreed to shower BioNTech with cash.
Via The Motley Fool · June 2, 2025

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.
By Pfizer Inc. · Via Business Wire · June 2, 2025

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them? It appears that these devils
Via Equities.com · June 2, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.
Via StockStory · June 1, 2025